Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.

A gain in chromosome 1q (+1q) is among the most common cytogenetic abnormalities in multiple myeloma (MM). It is unclear whether +1q is independently associated with decreased overall survival (OS). The objective of this study was to evaluate the impact of +1q on clinical characteristics, treatment response, and survival outcomes. We included 1376 Mayo Clinic patients diagnosed with MM from 2005 to 2018 who underwent fluorescence in situ hybridization testing at diagnosis with a panel including the +1q probe. A gain in 1q was found in 391 patients (28%) and was associated with anemia, hypercalcemia, high tumor burden, International Staging System (ISS) stage 3, high-risk (HR) translocations, and chromosome 13 abnormalities. There was no difference in overall response or deeper responses to proteasome inhibitor (PI)-, immunomodulatory drug (iMiD)-, or PI plus IMiD-based induction. Time to next treatment was shorter in patients with +1q compared with those without +1q (19.9 vs 27.7 months; P < .001). On univariate analysis, +1q was associated with increased risk of death (risk ratio [RR], 1.9; P < .001), and decreased OS was seen in all treatment groups. +1q was independently associated with decreased OS on multivariate analysis when other HR cytogenetic abnormalities, ISS stage 3, and age ≥70 years were included (RR, 1.5; P < .001). Gain of >1 copy of 1q was not associated with worse OS compared with gain of 1 copy (4.9 vs 4.3 years; P = .21). +1q was associated with high tumor burden, advanced disease stage, and HR translocations. It is independently associated with decreased OS, even in the setting of novel therapy and transplant.

[1]  P. Sonneveld,et al.  Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. , 2019, Blood advances.

[2]  Nisha S Joseph,et al.  Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone , 2019, Blood Cancer Journal.

[3]  C. Gross,et al.  Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. , 2019, Journal of Clinical Oncology.

[4]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[5]  M. Fullwood,et al.  Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. , 2018, Blood.

[6]  Yingyu Sun,et al.  MCL1 gene co‐expression module stratifies multiple myeloma and predicts response to proteasome inhibitor‐based therapy , 2018, Genes, chromosomes & cancer.

[7]  Shaji K. Kumar,et al.  The multiple myelomas — current concepts in cytogenetic classification and therapy , 2018, Nature Reviews Clinical Oncology.

[8]  G. Morgan,et al.  Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients , 2017, Leukemia.

[9]  S. Jhanwar,et al.  Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation , 2017, Leukemia & lymphoma.

[10]  V. Baladandayuthapani,et al.  Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[12]  F. Zhan,et al.  Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value , 2014, Haematologica.

[13]  Lust,et al.  Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. , 2012, Blood.

[14]  T. Buchler,et al.  Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  Robert A Kyle,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.

[16]  B. Barlogie,et al.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.

[17]  Cheng Li,et al.  Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. L. Bergsagel,et al.  A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy , 2007, Leukemia.

[19]  G. Ahmann,et al.  Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma , 2006, Leukemia.

[20]  Yongsheng Huang,et al.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.

[21]  J. Shaughnessy Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27 Kip1 and an aggressive clinical course in multiple myeloma , 2005, Hematology.

[22]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[24]  P. Sonneveld,et al.  Multiple myeloma , 2017, Nature Reviews Disease Primers.

[25]  P. L. Bergsagel,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. , 2013, Mayo Clinic proceedings.

[26]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.